Asia Pacific Brain Cancer Diagnostics Market Drivers and Forecasts by 2028

The brain cancer diagnostics market in Asia Pacific is expected to grow from US$ 178.6 million in 2021 to US$ 551.4 million by 2028; it is estimated to grow at a CAGR of 17.5% from 2021 to 2028.

Currently, there is insufficient evidence that they are less harmful than traditional cigarettes. Researchers at Wake Forest School of Medicine have discovered that nicotine promotes the spread of lung cancer cells to the brain, thereby forming deadly metastatic tumors. The study, published in the Journal of Experimental Medicine (JEM), suggests that nicotine replacement therapy may not be suitable for lung cancer patients trying to quit smoking. Thus, the increase in the number of cigarette smokers is bolstering the growth of the brain cancer diagnostics market.

The outbreak has severely affected the medical tourism industry in Asia pacific and imposed supply chain disruptions; moreover, low-income countries face additional challenges due to the shortage of healthcare infrastructure, restrictions imposed by hospitals to the suppliers, decreasing in demand of brain cancer diagnostics devices and others. Restrictive measures have been put forth in South Korea, Malaysia, Singapore, the Philippines, and India to prevent the disease transmission. These restrictive measures are anticipated to impact the supply chain and the availability of medical devices in these countries. It has affected disposable incomes and has also resulted in unemployment. Furthermore, business strategies such as acquisitions, mergers, and partnerships are adversely affected by the imposition of complete lockdown. Such obstructions in business activities are projected to hamper the adoption of various technologically advanced healthcare systems, including brain cancer diagnostics.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the brain cancer diagnostics market. The Asia Pacific brain cancer diagnostics market is expected to grow at a good CAGR during the forecast period.

Asia Pacific Brain Cancer Diagnostics Market Segmentation     

By Diagnostic Type

• Imaging Test
  • MRI
  • CT Scan
  • PET
• Biopsy
• Molecular Testing
• Lumbar Puncture
• Others

By Cancer Type

• Glioblastoma Multiforme
• Astrocytomas
• Ependymomas
• Others

By End User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

By Country

• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific

Companies Mentioned

• Thermo Fisher Scientific Inc.
• Siemens Healthineers A
• GE Healthcare
• Biocept, Inc.
• Koninklijke Philips N.V
• Canon Medical Systems
• Hitachi, Ltd.
• Neusoft Medical Systems

Asia Pacific Brain Cancer Diagnostics Report Scope